Connect your AI

Janux Therapeutics JANX Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Avalo TherapeuticsAVTX

$115.5K—

Vor BiopharmaVOR

——

Nektar TherapeuticsNKTR

——

AnnexonANNX

——

Other financials

Income statement

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

Market cap$889.15M-36.3%

Enterprise value$858.89M-36.2%

P/S64.8×-84.8×

Profitability

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Janux Therapeutics's payments of stock issuance costs?: Janux Therapeutics (JANX) reported payments of stock issuance costs of $0 in Q1 2026.